Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for AVTR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 597.00M
March 31, 2026 573.20M
December 31, 2025 623.80M
September 30, 2025 644.40M
June 30, 2025 681.80M
March 31, 2025 808.50M
December 31, 2024 840.80M
September 30, 2024 919.10M
June 30, 2024 905.00M
March 31, 2024 792.10M
December 31, 2023 870.00M
September 30, 2023 824.00M
June 30, 2023 851.60M
March 31, 2023 910.90M
Date Value
December 31, 2022 843.60M
September 30, 2022 939.00M
June 30, 2022 942.60M
March 31, 2022 978.90M
December 31, 2021 953.60M
September 30, 2021 958.60M
June 30, 2021 978.20M
March 31, 2021 803.60M
December 31, 2020 929.80M
September 30, 2020 710.80M
June 30, 2020 627.20M
March 31, 2020 532.10M
December 31, 2019 354.00M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Medpace Holdings, Inc. 752.66M
Champions Oncology, Inc. -4.472M
Personalis, Inc. -92.30M
Adaptive Biotechnologies Corp. -21.01M
10X Genomics, Inc. 127.08M